ADAM17 and cancer: Through the analysis of mutations in 32 types of cancers, we revealed that ADAM17 expression exhibited the highest mutation frequency, accounting for 10.53% of 57 cases of Uterine Carcinosarcomas, followed by Uterine Corpus Endometrial Carcinoma, accounting for 6.62% of 529 cases, whereas Kidney Renal Clear Cell Carcinoma had the lowest mutation rate, with 0.39% of 511 cases (Figure 1A).